Oya BAYDAR, Şennur ÖZEN, Burcu ÖZTÜRK ŞAHİN, Nurdan KÖKTÜRK, Mehmet Tevfik KİTAPÇI

Safety of an Inactivated SARS-CoV-2 Vaccine Among Healthcare Workers in Turkey: An Online Survey

Background: As vaccination against coronavirus disase-19 (COVID-19) evolves, hesitancy has become a problematic issue that has gradually spread worldwide. The main reason for vaccine hesitancy is uncertainties about vaccine side effects. Aims: To evaluate the safety of an inactivated COVID-19 vaccine, CoronaVac, and determine the risk factors of emergence of side effects. Study Design: Cross-sectional study. Methods: An online questionnaire was administered via the internet to healthcare workers who received one or two doses of CoronaVac. The online survey consisted of three sections detailing sociodemographic data, COVID-19 history, and post-vaccine side effects. Side effects that occurred in the period starting from immediately after the first vaccination to the end of the 14th day after the second vaccination were recorded. Results: A total of 1628 healthcare workers responded to the online survey. Of these, 24.3% had a side effect either after the first or second dose of CoronaVac. Redness and/or pain at the inoculation site, headache, muscle and joint pains, palpitations, and dizziness were the most common side effects. Female sex, age

PDF

___

1. https://www.worldometers.info/coronavirus/worldometer 2. Weiss P, Murdoch DR. Clinical course and mortality risk of severe COVID-19. Lancet. 2020;395:1014-1015. [CrossRef]
3. Pulendran B, Ahmed R. Immunological mechanisms of vaccination. Nat Immunol. 2011;12:509-517. [CrossRef]
4. Mallapaty S. China COVID vaccine reports mixed results - what does that mean for the pandemic? Nature. 2021. Epub ahead of print. PMID: 33452510. [CrossRef]
5. Dubé E, Gagnon D, MacDonald NE; SAGE Working Group on Vaccine Hesitancy. Strategies intended to address vaccine hesitancy: review of published reviews. Vaccine. 2015;33:4191-4203. [CrossRef]
6. Doroftei B, Ciobica A, Ilie OD, Maftei R, Ilea C. Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines. Diagnostics (Basel). 2021;11:579. [CrossRef]
7. Tanriover MD, Doğanay HL, Akova M, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021;398:213-222. [CrossRef]
8. Ella R, Vadrevu KM, Jogdand H, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. Lancet Infect Dis. 2021;21:637-646. Erratum in: Lancet Infect Dis. 2021;21:e81. [CrossRef]
9. Che Y, Liu X, Pu Y, et al. Randomized, Double-Blinded, Placebo-Controlled Phase 2 Trial of an Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in Healthy Adults. Clin Infect Dis. 2021;73:3949-3955. [CrossRef]
10. Riad A, Sağıroğlu D, Üstün B, et al. Prevalence and Risk Factors of CoronaVac Side Effects: An Independent Cross-Sectional Study among Healthcare Workers in Turkey. J Clin Med. 2021;10:2629.
11. Zhang MX, Zhang TT, Shi GF, et al. Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China. Expert Rev Vaccines. 202120:891-898. [CrossRef]
12. Food and Health Bureau (FHB). Report on Evaluation of Safety, Efficacy and Quality of CoronaVac COVID-19 Vaccine (Vero Cell) Inactivated. 2021. Available online: https://www.fhb.gov.hk/download/our_work/health/201200/e_evaluation_report_ CoronaVac.pdf (accessed on 1 April 2021)
13. (https://www.ttb.org.tr/makale_goster.php?Guid=6dc46898-d802-11eb-9450- 8a9f7b8c4cda.).
14. Chen G, Li X, Gong Z, et al. Hypertension as a sequela in patients of SARS-CoV-2 infection. PLoS One. 2021;16:e0250815. [CrossRef]
15. Meylan S, Livio F, Foerster M, et al. Stage III Hypertension in Patients After mRNA- Based SARS-CoV-2 Vaccination. Hypertension. 2021;77:56-57. [CrossRef]
16. https://www.mobihealthnews.com/news/covid-19-pandemic-leads-more-people- high-blood-pressure-research-suggests
17. Brancatella A, Ricci D, Cappellani D, et al. Is Subacute Thyroiditis an Underestimated Manifestation of SARS-CoV-2 Infection? Insights From a Case Series. J Clin Endocrinol Metab. 2020;105:dgaa537. [CrossRef]
18. Brancatella A, Ricci D, Viola N, Sgrò D, Santini F, Latrofa F. Subacute Thyroiditis After Sars-COV-2 Infection. J Clin Endocrinol Metab. 2020;105:dgaa276. [CrossRef]
19. Ippolito S, Dentali F, Tanda ML. SARS-CoV-2: a potential trigger for subacute thyroiditis? Insights from a case report. J Endocrinol Invest. 2020;43:1171-1172. [CrossRef]
20. Asfuroglu Kalkan E, Ates I. A case of subacute thyroiditis associated with Covid-19 infection. J Endocrinol Invest. 2020;43:1173-1174. [CrossRef]